Cargando…
Pituitary carcinoma: Two case reports and review of literature
BACKGROUND: Pituitary carcinoma is a rare type of malignancy that can be very difficult to diagnose and treat. Many cases were diagnosed at autopsy. Delays in diagnosis often adversely impact patients' outcomes. Even with prompt diagnosis, treatment decisions remain challenging in the absence o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046923/ https://www.ncbi.nlm.nih.gov/pubmed/32133278 http://dx.doi.org/10.5306/wjco.v11.i2.91 |
_version_ | 1783502040119377920 |
---|---|
author | Xu, Lai Khaddour, Karam Chen, Jie Rich, Keith M Perrin, Richard J Campian, Jian Li |
author_facet | Xu, Lai Khaddour, Karam Chen, Jie Rich, Keith M Perrin, Richard J Campian, Jian Li |
author_sort | Xu, Lai |
collection | PubMed |
description | BACKGROUND: Pituitary carcinoma is a rare type of malignancy that can be very difficult to diagnose and treat. Many cases were diagnosed at autopsy. Delays in diagnosis often adversely impact patients' outcomes. Even with prompt diagnosis, treatment decisions remain challenging in the absence of randomized controlled trials. CASE SUMMARY: We report two cases of pituitary carcinoma in men with a history of pituitary adenoma. In the first case, a 55-year-old man was initially diagnosed with pituitary macroadenoma. He underwent subtotal debulking of the tumor followed by adjuvant radiotherapy. Subsequently, he developed relapsed disease and multifocal intracranial metastases and a diagnosis of pituitary carcinoma was rendered. He passed away despite several lines of systemic therapies including temozolomide, lomustine and bevacizumab. Another 52-year-old man was diagnosed with atypical pituitary adenoma with presentation of sudden onset of vision loss in the right eye. He had recurrent pituitary carcinoma with spinal metastases, treated with surgery, radiation and temozolomide. CONCLUSION: Pituitary carcinoma is a rare neoplasm with poor prognosis that is difficult to diagnose and treat. The small number of cases restricts our ability to design randomized clinical trials. Management is largely driven by retrospective studies and case series. Establishing molecular biomarkers and comprehensive genomic profiling could help in decisions about diagnosis and management of pituitary carcinoma. |
format | Online Article Text |
id | pubmed-7046923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-70469232020-03-04 Pituitary carcinoma: Two case reports and review of literature Xu, Lai Khaddour, Karam Chen, Jie Rich, Keith M Perrin, Richard J Campian, Jian Li World J Clin Oncol Case Report BACKGROUND: Pituitary carcinoma is a rare type of malignancy that can be very difficult to diagnose and treat. Many cases were diagnosed at autopsy. Delays in diagnosis often adversely impact patients' outcomes. Even with prompt diagnosis, treatment decisions remain challenging in the absence of randomized controlled trials. CASE SUMMARY: We report two cases of pituitary carcinoma in men with a history of pituitary adenoma. In the first case, a 55-year-old man was initially diagnosed with pituitary macroadenoma. He underwent subtotal debulking of the tumor followed by adjuvant radiotherapy. Subsequently, he developed relapsed disease and multifocal intracranial metastases and a diagnosis of pituitary carcinoma was rendered. He passed away despite several lines of systemic therapies including temozolomide, lomustine and bevacizumab. Another 52-year-old man was diagnosed with atypical pituitary adenoma with presentation of sudden onset of vision loss in the right eye. He had recurrent pituitary carcinoma with spinal metastases, treated with surgery, radiation and temozolomide. CONCLUSION: Pituitary carcinoma is a rare neoplasm with poor prognosis that is difficult to diagnose and treat. The small number of cases restricts our ability to design randomized clinical trials. Management is largely driven by retrospective studies and case series. Establishing molecular biomarkers and comprehensive genomic profiling could help in decisions about diagnosis and management of pituitary carcinoma. Baishideng Publishing Group Inc 2020-02-24 2020-02-24 /pmc/articles/PMC7046923/ /pubmed/32133278 http://dx.doi.org/10.5306/wjco.v11.i2.91 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Xu, Lai Khaddour, Karam Chen, Jie Rich, Keith M Perrin, Richard J Campian, Jian Li Pituitary carcinoma: Two case reports and review of literature |
title | Pituitary carcinoma: Two case reports and review of literature |
title_full | Pituitary carcinoma: Two case reports and review of literature |
title_fullStr | Pituitary carcinoma: Two case reports and review of literature |
title_full_unstemmed | Pituitary carcinoma: Two case reports and review of literature |
title_short | Pituitary carcinoma: Two case reports and review of literature |
title_sort | pituitary carcinoma: two case reports and review of literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046923/ https://www.ncbi.nlm.nih.gov/pubmed/32133278 http://dx.doi.org/10.5306/wjco.v11.i2.91 |
work_keys_str_mv | AT xulai pituitarycarcinomatwocasereportsandreviewofliterature AT khaddourkaram pituitarycarcinomatwocasereportsandreviewofliterature AT chenjie pituitarycarcinomatwocasereportsandreviewofliterature AT richkeithm pituitarycarcinomatwocasereportsandreviewofliterature AT perrinrichardj pituitarycarcinomatwocasereportsandreviewofliterature AT campianjianli pituitarycarcinomatwocasereportsandreviewofliterature |